<DOC>
	<DOCNO>NCT02202395</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety Hydroxytriptolide ( LTS ) active rheumatoid arthritis patient inadequate response methotrexate .</brief_summary>
	<brief_title>Hydroxytriptolide Active Rheumatoid Arthritis Patients With Inadequate Response Methotrexate</brief_title>
	<detailed_description>1 . Investigate efficacy Hydroxytriptolide active RA patient 2 . Investigate safety Hydroxytriptolide active RA patient . Especially female reproductive system . 3 . Population PK study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>3565 year old , female , postmenopausal , parous , nulliparous fertility requirement 1987 ACR Diagnostic criterion 2009 ACR/EULAR Diagnostic criterion . X ray Evaluable Joint phase I/II/III , Joint Function Phase I/II/III Active RA Continuously take MTX least three month , ≥7.5mg/week . Before first study dose , keep stable MTX dose least 4 week Keep stable NSAIDs dose lowdose glucocorticoid least 4 week first study dose Using nonprohibited combination therapy , keep stable dose least 7 day first study dose Using DMARD appropriate withdrawal period : Withdrawal 4 week : Sulfasalazine , Azathioprine , Chloroquine , *Hydroxychloroquine , Auranofin , Penicillamine , Traditional Chinese medicine preparation ( TGP , Sinomenine ) Withdrawal 8 week : Leflunomide Withdrawal 8 week : Intramuscular , intravenous , intraarticular injection glucocorticoid Women fertility , negative pregnancy test , agree take contraceptive measure physical Voluntary inform consent Willing follow require regimen schedule , followup examination 1 . Currently suffer suffer inflammatory joint disease , mixed connective tissue disease , scleroderma , systemic lupus erythematosus , ankylose spondylitis , psoriatic arthritis , Reiter 's syndrome , bone arthritis , rheumatoid arthritis , gouty arthritis , diagnosis arthritis 16yrs 2 . With severe nonarticular manifestation high fever , interstitial pneumonia , pleurisy , pericarditis , severe vasculitis , neuropathy , etc . 3 . The evaluable joint underwent surgical treatment within 2 month 4 . Currently recent serious , progression , disease history control , include : liver , kidney , blood , gastrointestinal , endocrine , metabolic , respiratory , cardiovascular , nervous system diseases 5 . Currently malignancy , lymphoproliferative disease history 6 . Continuously use Tripterygium preparation three month effect 7 . History use TNFa inhibitor biological agent . ( Adalimumab , infliximab , etanercept ) 8 . Severe persistent infection within 3 month 9 . Xray show active pulmonary infection 10 . HBV , HCV , HIV , AIDS 11 . WBC &lt; 4.0×10^9/L , PLT &lt; 100×10^9/L , Hb &lt; 85g/L 12 . AST &gt; 2×ULN , ALT &gt; 2×ULN 13 . Cr &gt; 135umol/L 14 . Used oral contraceptive druds within 3 month 15 . Pregnancy test positive lactating patient patient birth preparation 16 . Have use prohibit drug 17 . With clinical symptom serious history drug abuse alcohol abuse 18 . History durg clinical trial within 3 month 19 . Allergy tripterygium 20 . Other reason depend investigator</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hydroxytriptolide</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>T8</keyword>
	<keyword>LTS</keyword>
</DOC>